Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats

Psychopharmacology
Charles W SchindlerMichael H Baumann

Abstract

3,4-Methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) are synthetic drugs found in so-called "bath salts" products. Both drugs exert their effects by interacting with monoamine transporter proteins. MDPV is a potent uptake blocker at transporters for dopamine and norepinephrine while methylone is a non-selective releaser at transporters for dopamine, norepinephrine, and serotonin (5-HT). We hypothesized that prominent 5-HT-releasing actions of methylone would render this drug less reinforcing than MDPV. To test this hypothesis, we compared behavioral effects of MDPV and methylone using intravenous (i.v.) self-administration on a fixed-ratio 1 schedule in male rats. Additionally, neurochemical effects of the drugs were examined using in vivo microdialysis in nucleus accumbens, in a separate cohort of rats. MDPV self-administration (0.03 mg/kg/inj) was acquired rapidly and reached 40 infusions per session, similar to the effects of cocaine (0.5 mg/kg/inj), by the end of training. In contrast, methylone self-administration (0.3 and 0.5 mg/kg/inj) was acquired slowly, and response rates only reached 20 infusions per session by the end of training. In dose substitution studies, MDPV and cocaine d...Continue Reading

References

Mar 20, 2003·Psychopharmacology·Leigh V PanlilioCharles W Schindler
Jul 11, 2006·Pharmacology, Biochemistry, and Behavior·Sunmee Wee, William L Woolverton
Nov 17, 2007·The European Journal of Neuroscience·Susan SchenkDeborah C Mash
Feb 7, 2009·The Journal of Pharmacology and Experimental Therapeutics·Dorota ZolkowskaMichael H Baumann
Jan 14, 2011·The Journal of Pharmacology and Experimental Therapeutics·Michael H BaumannRichard B Rothman
May 24, 2011·Pharmacology, Biochemistry, and Behavior·Charles W SchindlerLeigh V Panlilio
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael H BaumannNicholas V Cozzi
Apr 19, 2012·British Journal of Pharmacology·Raul López-ArnauJorge Camarasa
Aug 18, 2012·British Journal of Pharmacology·L D SimmlerM E Liechti
Oct 18, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael H BaumannCharles W Schindler
Nov 23, 2012·British Journal of Pharmacology·Krasnodara N CameronLouis J De Felice
Dec 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William E FantegrossiKenner C Rice
Apr 16, 2013·Biochemical Pharmacology·Amy J EshlemanAaron Janowsky
Jul 5, 2013·Journal of Forensic Sciences·Kilak KeshaDavid R Fowler
Jul 11, 2013·Behavioural Pharmacology·Michael B GatchMichael J Forster
Aug 6, 2013·Life Sciences·Christopher L GermanGlen R Hanson
Aug 8, 2013·Journal of Forensic Sciences·Trista H WrightKenneth E Ferslew
Apr 18, 2014·Basic & Clinical Pharmacology & Toxicology·Louise KarlssonFredrik C Kugelberg
Jul 31, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eugene A KiyatkinYavin Shaham
Sep 23, 2014·Journal of Psychopharmacology·Raúl López-ArnauJorge Camarasa
Nov 5, 2014·Journal of Psychoactive Drugs·Patrick S Johnson, Matthew W Johnson
Jan 21, 2015·Neuropharmacology·Kevin M CreehanMichael A Taffe

❮ Previous
Next ❯

Citations

Jan 8, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Blake A HutsellS Stevens Negus
Oct 27, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua S ElmoreMichael H Baumann
Feb 22, 2017·Progress in Neuro-psychopharmacology & Biological Psychiatry·R López-ArnauE Escubedo
Aug 29, 2018·The Journal of Pharmacology and Experimental Therapeutics·Megan J MoerkeS Stevens Negus
Dec 9, 2017·The Journal of Pharmacology and Experimental Therapeutics·Brenda M GannonGregory T Collins
Jun 4, 2019·International Journal of Legal Medicine·Fabio De-GiorgioMatteo Marti
Feb 12, 2020·British Journal of Clinical Pharmacology·Raquel Santos-ToscanoColin Davidson
Feb 27, 2020·Behavioural Pharmacology·William S HyattWilliam E Fantegrossi
Apr 29, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amy R JohnsonS Stevens Negus
Jun 24, 2018·Neurotoxicity Research·Teresa CocciniUliana De Simone
May 10, 2020·The Journal of Pharmacology and Experimental Therapeutics·Charlotte P MageeAnnette E Fleckenstein
Jun 17, 2020·Journal of Psychopharmacology·Michael B Gatch, Michael J Forster
Jul 6, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brenda M GannonGregory T Collins
Jun 18, 2018·Psychopharmacology·Mehrak Javadi-PaydarMichael A Taffe
Nov 26, 2020·Psychopharmacology·Michelle R DoyleGregory T Collins
Apr 29, 2021·The International Journal of Neuropsychopharmacology·Alison G P WakefordCarol A Paronis
Apr 1, 2021·The Journal of Pharmacology and Experimental Therapeutics·Nicole CentazzoMarta Concheiro
Jun 9, 2021·Archives of Toxicology·Jorge SoaresJoão Paulo Capela
Aug 8, 2021·International Journal of Molecular Sciences·Laia Alegre-ZuranoOlga Valverde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Michael H BaumannCharles W Schindler
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Michael H BaumannRichard B Rothman
The Journal of Pharmacology and Experimental Therapeutics
Paul W CzotyLeonard L Howell
© 2021 Meta ULC. All rights reserved